Tirzepatide escalates from 2.5mg to 5mg, 7.5mg, 10mg, 12.5mg, and 15mg in 4-week steps
Liraglutide, semaglutide and tirzepatide are European Medicines Agency approved to improve metabolic control in T2DM and to decrease weight in persons with obesity [body mass index (BMI) 30 kg/m 2 ] or with overweight (BMI 27 kg/m 2 ) associated with weight-related comorbidities such as hypertension, dyslipidaemia, CVD and others
Patients want to know where to go, what services are available, and how to take the next step
It was originally developed for type 2 diabetes management (Ozempic) but showed such dramatic weight loss effects that the FDA approved a higher-dose formulation for chronic weight management (Wegovy)
Keeping track of side effects During your Janumet or Janumet XR treatment, consider taking notes on any side effects youre having
GLP-1 receptor agonists enhance glucose-dependent insulin secretion from pancreatic beta cells, suppress inappropriate glucagon release, and slow gastric emptying